Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

(2011) S. Faivre et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma

(2010) Robert J. Motzer et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

(2010) D. Koeberle et al.   ONCOLOGIST

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

(2009) S. E. DePrimo et al.   CLINICAL CANCER RESEARCH

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

(2009) Marja Lohela et al.   CURRENT OPINION IN CELL BIOLOGY

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

Expression of VEGF-C Correlates with a Poor Prognosis Based on Analysis of Prognostic Factors in 73 Patients with Esophageal Squamous Cell Carcinomas

(2009) P. Liu et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

(2009) Sandrine Faivre et al.   LANCET ONCOLOGY

Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies

(2009) Puneeta Tandon et al.   LIVER INTERNATIONAL

C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice

(2008) Belinda Knight et al.   GASTROENTEROLOGY

VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma

(2008) Armin Thelen et al.   INTERNATIONAL JOURNAL OF CANCER

Clinical Significance of Plasma Level of Vascular Endothelial Growth Factor-C in Patients with Colorectal Cancer

(2008) T. Miyazaki et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE